HC Wainwright Lifts Earnings Estimates for Vivani Medical

Vivani Medical, Inc. (NASDAQ:VANI) – Stock analysts at HC Wainwright increased their Q1 2026 EPS estimates for Vivani Medical in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.08) per share for the quarter, up from their prior forecast of ($0.09). HC Wainwright has a “Buy” rating and a $3.50 price objective on the stock. The consensus estimate for Vivani Medical’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Vivani Medical’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.30) EPS.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, January 9th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $3.50.

Vivani Medical Stock Performance

VANI stock opened at $1.08 on Friday. Vivani Medical has a one year low of $0.91 and a one year high of $1.92. The firm has a market cap of $91.42 million, a PE ratio of -2.51 and a beta of 2.16. The firm’s 50 day moving average price is $1.22 and its 200-day moving average price is $1.35.

Vivani Medical (NASDAQ:VANI) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01.

Hedge Funds Weigh In On Vivani Medical

Large investors have recently made changes to their positions in the stock. Tudor Investment Corp ET AL purchased a new position in shares of Vivani Medical during the 4th quarter worth approximately $1,127,000. Geode Capital Management LLC raised its position in Vivani Medical by 29.6% in the fourth quarter. Geode Capital Management LLC now owns 461,652 shares of the company’s stock valued at $568,000 after purchasing an additional 105,398 shares during the period. State Street Corp lifted its stake in Vivani Medical by 12.5% during the fourth quarter. State Street Corp now owns 144,865 shares of the company’s stock worth $178,000 after purchasing an additional 16,070 shares in the last quarter. Marshall Wace LLP acquired a new position in Vivani Medical during the fourth quarter worth $174,000. Finally, Renaissance Technologies LLC boosted its position in shares of Vivani Medical by 118.4% during the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock worth $121,000 after buying an additional 53,127 shares during the period. 6.78% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Gregg Williams bought 1,737,765 shares of the stock in a transaction on Thursday, January 15th. The stock was bought at an average price of $1.14 per share, with a total value of $1,981,052.10. Following the completion of the purchase, the director directly owned 26,564,109 shares in the company, valued at $30,283,084.26. This represents a 7.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have bought a total of 4,664,347 shares of company stock worth $5,666,549 over the last ninety days. Company insiders own 46.40% of the company’s stock.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.